Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer

Prostate

Volumn 72, Issue 15, 2012, Pages 1628-1637

  Wang, Jennifer Y ^a   Swami, Srilatha ^a   Krishnan, Aruna V ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

calcitriol; CYP24A1; hypercalcemia; prostate cancer; soy; vitamin D

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CALBINDIN; CALCITRIOL; CYCLIN D1; CYCLOOXYGENASE 2; PROSTAGLANDIN RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; SOMATOMEDIN BINDING PROTEIN 3; SOYBEAN PROTEIN; VANILLOID RECEPTOR 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; LD 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; VITAMIN BLOOD LEVEL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CALCITRIOL; CELL CYCLE; CELL PROLIFERATION; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERCALCEMIA; MALE; MICE; MICE, NUDE; PROSTAGLANDINS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SOYBEAN PROTEINS; VITAMINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867081993     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22516     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
2. Beer TM, Myrthue A,. Calcitriol in the treatment of prostate cancer. Anticancer Res 2006; 26 (4A): 2647-2651.
3. Chen TC, Holick MF,. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003; 14 (9): 423-430.
4. Gross C, Stamey T, Hancock S, Feldman D,. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159 (6): 2035-2039; discussion 2039-2040.
5. Krishnan AV, Feldman D,. Molecular pathways mediating the anti-inflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 2010; 17 (1): R19-R38.
6. Schwartz GG,. Vitamin D and intervention trials in prostate cancer: From theory to therapy. Ann Epidemiol 2009; 19 (2): 96-102.
7. Stewart LV, Weigel NL,. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 2005; 64 (1): 9-19.
8. Swami S, Krishnan AV, Feldman D,. Vitamin D metabolism and action in the prostate: Implications for health and disease. Mol Cell Endocrinol 2011; 347 (1-2): 61-69.
9. Deeb KK, Trump DL, Johnson CS,. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 2007; 7 (9): 684-700.
10. Fleet JC,. Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 2008; 29 (6): 388-396.
11. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM, Feldman D,. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 2007; 103 (3-5): 694-702.
12. Krishnan AV, Peehl DM, Feldman D,. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003; 88 (2): 363-371.
13. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 (4): 256-269.
14. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H,. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42 (1): 73-78.
15. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D,. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: Role of anti-inflammatory activity. J Bone Miner Res 2007; 22 (Suppl 2): V74-V80.
16. Krishnan AV, Srinivas S, Feldman D,. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinol 2009; 1 (1): 7-11.
17. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D,. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005; 65 (17): 7917-7925.
18. Barnes S,. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995; 125 (3 Suppl): 777S-783S.
19. Constantinou A, Huberman E,. Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc Soc Exp Biol Med 1995; 208 (1): 109-115.
20. Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ,. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2008; 11 (1): 6-12.
21. Li Y, Sarkar FH,. Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 2002; 132 (12): 3623-3631.
22. Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, Peehl DM, Feldman D,. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer 2009; 124 (9): 2050-2059.
23. Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD,. Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004; 64 (6): 2143-2147.
24. Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD,. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 2002; 132 (10): 3191-3194.
25. Wietzke JA, Welsh J,. Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. J Steroid Biochem Mol Biol 2003; 84 (2-3): 149-157.
26. Swami S, Krishnan AV, Peehl DM, Feldman D,. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005; 241 (1-2): 49-61.
27. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D,. Calcitriol and genistein actions to inhibit the prostaglandin pathway: Potential combination therapy to treat prostate cancer. J Nutr 2007; 137 (1 Suppl): 205S-210S.
28. Krishnan AV, Trump DL, Johnson CS, Feldman D,. The Role of Vitamin D in Cancer Prevention and Treatment. Endocrinol Metab Clin North Am 2010; 39 (2): 401-418.
29. Fleet JC, Gliniak C, Zhang Z, Xue Y, Smith KB, McCreedy R, Adedokun SA,. Serum metabolite profiles and target tissue gene expression define the effect of cholecalciferol intake on calcium metabolism in rats and mice. J Nutr 2008; 138 (6): 1114-1120.
30. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL,. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3 (4): 402-408.
31. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL,. Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem 1996; 42 (4): 586-592.
32. Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS,. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 2004; 66 (1): 62-66.
33. Peng L, Malloy PJ, Feldman D,. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004; 18 (5): 1109-1119.
34. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL,. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007; 59 (5): 581-587.
35. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G,. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29 (16): 2191-2198.
36. Yang ES, Burnstein KL,. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003; 278 (47): 46862-46868.
37. Krishnan AV, Feldman D,. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51: 311-336.
38. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H,. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 2004; 45 (2): 245-251; discussion 251.
39. Lund TD, Munson DJ, Adlercreutz H, Handa RJ, Lephart ED,. Androgen receptor expression in the rat prostate is down-regulated by dietary phytoestrogens. Reprod Biol Endocrinol 2004; 2: 5.
40. Kallay E, Adlercreutz H, Farhan H, Lechner D, Bajna E, Gerdenitsch W, Campbell M, Cross HS,. Phytoestrogens regulate vitamin D metabolism in the mouse colon: Relevance for colon tumor prevention and therapy. J Nutr 2002; 132 (11 Suppl): 3490S-3493S.
41. Farhan H, Wahala K, Cross HS,. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 2003; 84 (4): 423-429.
42. Farhan H, Cross HS,. Transcriptional inhibition of CYP24 by genistein. Ann N Y Acad Sci 2002; 973: 459-462.
43. Ly LH, Zhao XY, Holloway L, Feldman D,. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999; 140 (5): 2071-2076.
44. Peehl DM, Seto E, Hsu JY, Feldman D,. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 2002; 168 (4 Pt 1): 1583-1588.
45. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D,. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25 (2): 144-146.
46. King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N,. The vitamin D/CYP24A1 story in cancer. Anticancer Agents Med Chem 2010; 10 (3): 213-224.
47. Brown AJ,. Mechanisms for the selective actions of vitamin D analogues. Curr Pharm Des 2000; 6 (7): 701-716.
48. Posner GH, Helvig C, Cuerrier D, Collop D, Kharebov A, Ryder K, Epps T, Petkovich M,. Vitamin D analogues targeting CYP24 in chronic kidney disease. J Steroid Biochem Mol Biol 2010; 121 (1-2): 13-19.
49. Yee SW, Simons C,. Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives. Bioorg Med Chem Lett 2004; 14 (22): 5651-5654.
50. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB, Glorieux FH,. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000; 141 (7): 2658-2666.
51. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H, Wingen AM, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M,. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011; 365 (5): 410-421.
52. Fleet JC, Schoch RD,. Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Crit Rev Clin Lab Sci 2010; 47 (4): 181-195.
53. Hoenderop JG, Nilius B, Bindels RJ,. Epithelial calcium channels: From identification to function and regulation. Pflugers Arch 2003; 446 (3): 304-308.
54. van de Graaf SF, Boullart I, Hoenderop JG, Bindels RJ,. Regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1alpha,25-dihydroxy Vitamin D3 and dietary Ca2+. J Steroid Biochem Mol Biol 2004; 89-90 (1-5): 303-308.